Arthritis

New Biosimilar approval (biologic generic) may save billions in costs for rheumatoid arthritis patients

man with son The biosimilar adventure continues-Somewhat like generic medicines, A new biosimilar for infliximab or (Remicade) got the approval not from the FDA. What this means is that the medicine works to combat rheumatoid arthritis and Chrohn's disease, but costs much much less that the well-known brand.

Shock at the Pharmacy Drive Up Window

Something is fishy  After lunch I stopped at a large Pharmacy chain to hand in 2 written prescriptions and to ask for a refill on one of the other prescriptions that my doctor had just called in. Three prescriptions, nothing unusual. (little did I know, something was fishy).

Mysimba (Contrave-Naltexone plus bupropion in the EU) now approved for weight loss

Mysimba for weight loss- It is the name for Contrave (naltrexone and bupropion) in Europe. This drug is the newest weight loss drug and had an unusual release of data. What appears to be shown in early data is that it may have a direct effect/benefit in decreasing risk of heart attack.

Weight loss drug decreases heart attacks? Contrave and early data

 

Members Only: 

 

fireworks A study of 4,500 patients using a new weight loss drug called Contrave (bupriprion and naltrexone) had the expected effect of a weight loss benefit, and the drug was FDA approved. A study of 8,910 people in a follow up study had the weight loss benefit, however; the patients taking Contrave had fewer heart attacks than the people who didn't take it.

There is controversy over this trial and apparent early leaks of data, but the information that patients taking the drug had fewer heart attacks is stunning. Importantly, the researchers doing the study thought the benefit on heart attacks may be a direct effect of the drug combination!

More to follow as always.

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.